Cogent Biosciences Presents Cancer Research

Cogent Biosciences will present new data on its pan-KRAS(ON) inhibitor, CGT1263, at the American Association for Cancer Research Annual Meeting. The poster presentations will showcase the drug's selectivity profile, which could potentially reduce side effects like skin toxicity. This research is a critical step in advancing the development of targeted therapies for cancer patients, particularly those with KRAS mutations.